Comment on: Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.
Comment on: Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.
复制标题
评论：选择性多巴胺 D3 受体部分激动剂/拮抗剂对猴羟考酮自我给药和抗伤害作用的影响。
DOI：
10.1038/s41386-023-01726-w
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Comer,SandraD
中科院分区：
文献类型：
--
作者：
Chong,Samantha;Comer,SandraD
阿片成瘾是美国普遍存在的公共卫生危机，需要创新的解决方案。每天有超过90名美国人死于阿片类药物过量，许多寻求阿片类药物使用障碍(OUD)治疗的患者无法获得治疗，原因是无法获得医疗保险，难以适应医疗保健系统，耻辱和种族偏见。尽管OUD盛行，但在美国只有三种FDA批准的药物可用于治疗这种疾病：纳曲酮、美沙酮和丁丙诺啡。所有这些针对OUD(Mouds)的药物都针对阿片受体，虽然所有这些药物在治疗OUD方面都有效，但每种药物都有一定的缺点(例如，呼吸抑制、非法使用、在诱导前需要阿片类药物解毒)。国家药物滥用研究所的目标之一是开发新的Moud，以便提供更多的治疗机会，这将潜在地降低OUD患者的死亡率。Woodlief和他的同事[1]进行了几项临床前研究，以评估针对非阿片受体的Mod。具体地说，他们的研究重点是多巴胺D3受体(D3R)。以前使用拮抗剂针对D3R的研究表明，在不影响吗啡诱导的镇痛的情况下，吗啡的耐受性和依赖性得到了降低，这表明这种方法可以保留阿片类药物的止痛效果，并允许使用较小剂量的阿片类药物，从而减少疼痛治疗的副作用，潜在地降低发生OUD的风险[2]。
Opioid addiction is a pervasive public health crisis in the United States (US) that requires innovative solutions. More than 90 Americans die from an opioid overdose every day, and many patients who seek treatment for opioid use disorder (OUD) are not able to receive it due to lack of access to health insurance, difficulties in navigating the health care system, stigma, and racial bias. Despite the prevalence of OUD, only three FDA-approved medications are available in the US to treat this disorder: naltrexone, methadone, and buprenorphine. All of these medications for OUD (MOUDs) target opioid receptors and although all of them are effective in treating OUD, each is associated with certain disadvantages (eg, respiratory depression, diversion for illicit use, need for opioid detoxification prior to induction). One of the goals of the National Institute on Drug Abuse is to develop new MOUDs in order to provide more accessibility for treatment which will potentially reduce mortality among those who struggle with OUD.Woodlief and colleagues [1] conducted several preclinical studies to evaluate MOUDs that target non-opioid receptors. Specifically, their research focused on the dopamine D3 receptor (D3R). Previous studies targeting the D3R with an antagonist showed that morphine tolerance and dependence were reduced without affecting morphine-induced analgesia, suggesting that this approach may preserve the analgesic effects of opioids and allow for the use of lower doses of opioids and hence fewer sideeffects in the treatment of pain and potentially a lower risk of developing OUD [2].